BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chaparro M, González Moreno L, Trapero-Marugán M, Medina J, Moreno-Otero R. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents. Aliment Pharmacol Ther 2008;28:1269-77. [PMID: 18808443 DOI: 10.1111/j.1365-2036.2008.03857.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Kim EK, Choi E. Pathological roles of MAPK signaling pathways in human diseases. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2010;1802:396-405. [DOI: 10.1016/j.bbadis.2009.12.009] [Cited by in Crossref: 1239] [Cited by in F6Publishing: 1201] [Article Influence: 103.3] [Reference Citation Analysis]
2 Mitsos A, Melas IN, Siminelakis P, Chairakaki AD, Saez-Rodriguez J, Alexopoulos LG. Identifying drug effects via pathway alterations using an integer linear programming optimization formulation on phosphoproteomic data. PLoS Comput Biol 2009;5:e1000591. [PMID: 19997482 DOI: 10.1371/journal.pcbi.1000591] [Cited by in Crossref: 100] [Cited by in F6Publishing: 76] [Article Influence: 7.7] [Reference Citation Analysis]
3 Iacobazzi RM, Porcelli L, Lopedota AA, Laquintana V, Lopalco A, Cutrignelli A, Altamura E, Di Fonte R, Azzariti A, Franco M, Denora N. Targeting human liver cancer cells with lactobionic acid-G(4)-PAMAM-FITC sorafenib loaded dendrimers. Int J Pharm 2017;528:485-97. [PMID: 28624661 DOI: 10.1016/j.ijpharm.2017.06.049] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
4 Koehler BC, Urbanik T, Vick B, Boger RJ, Heeger S, Galle PR, Schuchmann M, Schulze-Bergkamen H. TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies. World J Gastroenterol 2009; 15(47): 5924-5935 [PMID: 20014456 DOI: 10.3748/wjg.15.5924] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
5 Wu L, Liu S, Wei J, Li D, Liu X, Wang J, Wang L. Synthesis and biological evaluation of matrine derivatives as anti-hepatocellular cancer agents. Bioorg Med Chem Lett 2016;26:4267-71. [PMID: 27481558 DOI: 10.1016/j.bmcl.2016.07.045] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
6 Chen JY, Chen YJ, Yen CJ, Chen WS, Huang WC. HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3. Oncotarget 2016;7:473-89. [PMID: 26595522 DOI: 10.18632/oncotarget.6337] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
7 Hsu CY, Liu PH, Lee YH, Hsia CY, Huang YH, Chiou YY, Lin HC, Huo TI. Hepatocellular Carcinoma Patients With Performance Status 1 Deserve New Classification and Treatment Algorithm in the BCLC System. Medicine (Baltimore) 2015;94:e1223. [PMID: 26200647 DOI: 10.1097/MD.0000000000001223] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
8 Hollebecque A, Cattan S, Romano O, Sergent G, Mourad A, Louvet A, Dharancy S, Boleslawski E, Truant S, Pruvot FR. Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score. Aliment Pharmacol Ther. 2011;34:1193-1201. [PMID: 21958438 DOI: 10.1111/j.1365-2036.2011.04860.x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 75] [Article Influence: 7.2] [Reference Citation Analysis]
9 Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Evers BM. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation. J Surg Res. 2012;176:542-548. [PMID: 22261591 DOI: 10.1016/j.jss.2011.10.045] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 4.9] [Reference Citation Analysis]
10 Nishiofuku H, Marugami N, Tanaka T, Anai H, Maeda S, Masada T, Takano M, Mitoro A, Kichikawa K. Isolated fat-containing pancreatic metastasis from hepatocellular carcinoma. Jpn J Radiol. 2013;31:408-411. [PMID: 23539254 DOI: 10.1007/s11604-013-0193-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
11 Cabrera R, Pannu DS, Caridi J, Firpi RJ, Soldevila-Pico C, Morelli G, Clark V, Suman A, George TJ Jr, Nelson DR. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. Aliment Pharmacol Ther 2011;34:205-13. [PMID: 21605146 DOI: 10.1111/j.1365-2036.2011.04697.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 76] [Article Influence: 6.1] [Reference Citation Analysis]
12 Kim H, Lim HY. Novel EGFR-TK inhibitor EKB-569 inhibits hepatocellular carcinoma cell proliferation by AKT and MAPK pathways. J Korean Med Sci 2011;26:1563-8. [PMID: 22147992 DOI: 10.3346/jkms.2011.26.12.1563] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
13 Shi J, Chen J, Wang J, Zhu Y. Binding interaction between sorafenib and calf thymus DNA: Spectroscopic methodology, viscosity measurement and molecular docking. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 2015;136:443-50. [DOI: 10.1016/j.saa.2014.09.056] [Cited by in Crossref: 77] [Cited by in F6Publishing: 68] [Article Influence: 11.0] [Reference Citation Analysis]
14 Li G, Staveley-O'Carroll KF, Kimchi ET. Potential of Radiofrequency Ablation in Combination with Immunotherapy in the Treatment of Hepatocellular Carcinoma. J Clin Trials. 2016;6. [PMID: 28042519 DOI: 10.4172/2167-0870.1000257] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
15 Schattenberg JM, Galle PR. Show me your signaling--and I'll tell you who you are. J Hepatol 2009;51:638-9. [PMID: 19592126 DOI: 10.1016/j.jhep.2009.05.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
16 Rogério CPA, Daniele A, Betty G, Carla M, Monica V, Michele H, Deborah T, Mario K, Otavio G, Paula P. Advanced hepatocellular carcinoma. Review of targeted molecular drugs. Annals of Hepatology 2011;10:21-7. [DOI: 10.1016/s1665-2681(19)31582-0] [Cited by in Crossref: 53] [Article Influence: 4.8] [Reference Citation Analysis]
17 Wang Y, Wang L. Effect of Combined Sorafenib/Cisplatinum Treatment on the Autophagy and Proliferation of Hepatocellular Carcinoma hepG2 Cells in Vitro. Asian Pac J Cancer Prev 2020;21:2853-7. [PMID: 33112540 DOI: 10.31557/APJCP.2020.21.10.2853] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Di Costanzo GG, de Stefano G, Tortora R, Farella N, Addario L, Lampasi F, Lanza AG, Cordone G, Imparato M, Caporaso N. Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma. Future Oncology 2015;11:943-51. [DOI: 10.2217/fon.14.291] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
19 Guan Y, He Q. Sorafenib: activity and clinical application in patients with hepatocellular carcinoma. Expert Opinion on Pharmacotherapy 2011;12:303-13. [DOI: 10.1517/14656566.2011.546346] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
20 Martelletti C, Ricotti A, Gesualdo M, Carucci P, Gaia S, Rolle E, Burlone ME, Okolicsanyi S, Mattalia A, Pirisi M, Berchialla P, Tabone M. Radioembolization vs sorafenib in locally advanced hepatocellular carcinoma with portal vein tumor thrombosis: A propensity score and Bayesian analysis. J Dig Dis 2021;22:496-502. [PMID: 34189839 DOI: 10.1111/1751-2980.13030] [Reference Citation Analysis]
21 Kim MN, Ro SW, Kim DY, Kim da Y, Cho KJ, Park JH, Lim HY, Han KH. Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma. Cancer Chemother Pharmacol 2015;76:257-67. [PMID: 26037205 DOI: 10.1007/s00280-015-2787-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
22 Pinter M, Sieghart W, Hucke F, Graziadei I, Vogel W, Maieron A, Königsberg R, Weissmann A, Kornek G, Matejka J, Stauber R, Buder R, Grünberger B, Schöniger-Hekele M, Müller C, Peck-Radosavljevic M. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther 2011;34:949-59. [PMID: 21883324 DOI: 10.1111/j.1365-2036.2011.04823.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 5.4] [Reference Citation Analysis]
23 Zhang Q, Cheng S, Cao L, Yang J, Wang Y, Chen Y. LINC00978 promotes hepatocellular carcinoma carcinogenesis partly via activating the MAPK/ERK pathway. Biosci Rep 2020;40:BSR20192790. [PMID: 32077915 DOI: 10.1042/BSR20192790] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
24 Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, Gores G, Kerlan R, Merle P, O'Neil B, Poon R, Schwartz L, Tepper J, Yao F, Haller D, Mooney M, Venook A. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2010;28:3994-4005. [PMID: 20679622 DOI: 10.1200/jco.2010.28.7805] [Cited by in Crossref: 261] [Cited by in F6Publishing: 146] [Article Influence: 21.8] [Reference Citation Analysis]
25 Singh AR, Joshi S, Burgoyne AM, Sicklick JK, Ikeda S, Kono Y, Garlich JR, Morales GA, Durden DL. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma. Mol Cancer Ther 2016;15:2553-62. [PMID: 27496136 DOI: 10.1158/1535-7163.MCT-15-0976] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
26 Gramenzi A, Golfieri R, Mosconi C, Cappelli A, Granito A, Cucchetti A, Marinelli S, Pettinato C, Erroi V, Fiumana S, Bolondi L, Bernardi M, Trevisani F; BLOG (Bologna Liver Oncology Group). Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. Liver Int. 2015;35:1036-1047. [PMID: 24750853 DOI: 10.1111/liv.12574] [Cited by in Crossref: 69] [Cited by in F6Publishing: 67] [Article Influence: 8.6] [Reference Citation Analysis]
27 Craparo EF, Sardo C, Serio R, Zizzo MG, Bondì ML, Giammona G, Cavallaro G. Galactosylated polymeric carriers for liver targeting of sorafenib. International Journal of Pharmaceutics 2014;466:172-80. [DOI: 10.1016/j.ijpharm.2014.02.047] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 6.5] [Reference Citation Analysis]
28 Marra M, Sordelli IM, Lombardi A, Lamberti M, Tarantino L, Giudice A, Stiuso P, Abbruzzese A, Sperlongano R, Accardo M. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med. 2011;9:171. [PMID: 21985599 DOI: 10.1186/1479-5876-9-171] [Cited by in Crossref: 143] [Cited by in F6Publishing: 134] [Article Influence: 13.0] [Reference Citation Analysis]
29 Reker D, Rybakova Y, Kirtane AR, Cao R, Yang JW, Navamajiti N, Gardner A, Zhang RM, Esfandiary T, L'Heureux J, von Erlach T, Smekalova EM, Leboeuf D, Hess K, Lopes A, Rogner J, Collins J, Tamang SM, Ishida K, Chamberlain P, Yun D, Lytton-Jean A, Soule CK, Cheah JH, Hayward AM, Langer R, Traverso G. Computationally guided high-throughput design of self-assembling drug nanoparticles. Nat Nanotechnol 2021;16:725-33. [PMID: 33767382 DOI: 10.1038/s41565-021-00870-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
30 Qi X, Lam SS, Liu D, Kim DY, Ma L, Alleruzzo L, Chen W, Hode T, Henry CJ, Kaifi J, Kimchi ET, Li G, Staveley-O'Carroll KF. Development of inCVAX, In situ Cancer Vaccine, and Its Immune Response in Mice with Hepatocellular Cancer. J Clin Cell Immunol 2016;7:438. [PMID: 27656328 DOI: 10.4172/2155-9899.1000438] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
31 Singh MK, Das BK, Choudhary S, Gupta D, Patil UK. Diabetes and hepatocellular carcinoma: A pathophysiological link and pharmacological management. Biomed Pharmacother 2018;106:991-1002. [PMID: 30119271 DOI: 10.1016/j.biopha.2018.06.095] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
32 Tang K, Luo C, Li Y, Lu C, Zhou W, Huang H, Chen X. The study of a novel sorafenib derivative HLC-080 as an antitumor agent. PLoS One 2014;9:e101889. [PMID: 25004130 DOI: 10.1371/journal.pone.0101889] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
33 Schöniger-hekele M, Müller C. Pilot study: rapamycin in advanced hepatocellular carcinoma: Rapamycin in patients with hepatocellular carcinoma. Alimentary Pharmacology & Therapeutics 2010;32:763-8. [DOI: 10.1111/j.1365-2036.2010.04404.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
34 Santos NP, Colaço AA, Oliveira PA. Animal models as a tool in hepatocellular carcinoma research: A Review. Tumour Biol 2017;39:1010428317695923. [PMID: 28347231 DOI: 10.1177/1010428317695923] [Cited by in Crossref: 46] [Cited by in F6Publishing: 54] [Article Influence: 9.2] [Reference Citation Analysis]
35 Heinzow HS, Meister T, Nass D, Köhler M, Spieker T, Wolters H, Domschke W, Domagk D. Outcome of supraselective transarterial chemoembolization in patients with hepatocellular carcinoma. Scand J Gastroenterol 2011;46:201-10. [PMID: 20969491 DOI: 10.3109/00365521.2010.525256] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
36 Schütte K, Zimmermann L, Bornschein J, Csepregi A, Rühl R, Ricke J, Malfertheiner P. Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis. Digestion. 2011;83:275-282. [PMID: 21282952 DOI: 10.1159/000320377] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
37 Cabrera R, Limaye AR, Horne P, Mills R, Soldevila-Pico C, Clark V, Morelli G, Firpi R, Nelson DR. The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma. Aliment Pharmacol Ther 2013;37:91-7. [PMID: 23094860 DOI: 10.1111/apt.12098] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
38 Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs. 2009;69:223-240. [PMID: 19228077 DOI: 10.2165/00003495-200969020-00006] [Cited by in Crossref: 303] [Cited by in F6Publishing: 279] [Article Influence: 23.3] [Reference Citation Analysis]